Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
40:26
Benefit-Risk Considerations During Drug Product Development (8of14) REdI 2018
1:20:20
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
44:31
Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018
33:18
Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018
50:02
Cannabis Products and the Potential Impact on Patients
1:00:00
Clinical Pharmacology Considerations for Radiolabeled Mass Balance Studies
1:57:53
Clinical Pharmacology Considerations for Novel Therapeutic Modalities
28:11